Arcutis Biotherapeutics Clinical Site 18

Bexley, Ohio 43209

0 studies enrolling now · 3 studies all time

What they study most

Seborrheic Dermatitis

Studies at this site

• Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis — Completed
• Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) — Completed
• Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis — Completed